EU approval for Seebri Breezhaler (Novartis) for COPD - 02-Oct-2012

Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). This follows the September 28 approval of once-daily Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg in Japan.

Related News

Related Respiratory Information

Related Respiratory Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013